CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations.
about
C/EBPα Dysregulation in AML and ALLPrevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology GroupDistinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosminAllogeneic stem cell transplantation in first complete remissionMolecular prognostic factors in cytogenetically normal acute myeloid leukemiaCIViC databaseWilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B studyGene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B.Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis.Epigenetics in Cancer: A Hematological PerspectiveClinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise reviewCEBPA mutations in patients with de novo acute myeloid leukemia: data analysis in a Chinese populationProteomic identification of C/EBP-DBD multiprotein complex: JNK1 activates stem cell regulator C/EBPalpha by inhibiting its ubiquitination.CEBPA-double-mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biological features.IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.Genomic imbalances are confined to non-proliferating cells in paediatric patients with acute myeloid leukaemia and a normal or incomplete karyotype.Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features.Long-term follow-up of cytogenetically normal CEBPA-mutated AMLCEBPA point mutations in hematological malignancies.Double CEBPA mutations are prognostically favorable in non-M3 acute myeloid leukemia patients with wild-type NPM1 and FLT3-ITD.The multifaceted functions of C/EBPα in normal and malignant haematopoiesis.Prognostically important molecular markers in cytogenetically normal acute myeloid leukemia.C/EBPα regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutationsBAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemiaCharacterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia.Acute myelogenous leukemia at Baylor Charles A. Sammons Cancer Center, 2010 to 2012: retrospective analysis of molecular genetic evaluation.The N-terminal CEBPA mutant in acute myeloid leukemia impairs CXCR4 expressionIncidence and prognostic impact of DNMT3A mutations in Korean normal karyotype acute myeloid leukemia patients.FLT3-internal tandem duplication and age are the major prognostic factors in patients with relapsed acute myeloid leukemia with normal karyotypeC/EBPα and C/EBPα oncoproteins regulate nfkb1 and displace histone deacetylases from NF-κB p50 homodimers to induce NF-κB target genes.Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome.Unfolded protein response suppresses CEBPA by induction of calreticulin in acute myeloid leukaemia.Detection of nucleophosmin and FMS-like tyrosine kinase-3 gene mutations in acute myeloid leukemiaMolecular diagnostics in acute leukemias.Identification of let-7a-2-3p or/and miR-188-5p as prognostic biomarkers in cytogenetically normal acute myeloid leukemiaFLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era?Strategy for robust detection of insertions, deletions, and point mutations in CEBPA, a GC-rich content gene, using 454 next-generation deep-sequencing technology
P2860
Q22065117-DE869298-0D5C-4E86-81FA-9607D37406ADQ24602856-55CBC1B1-9F1D-4FC1-8BB8-9CAA9A18DC22Q24652323-AD909E74-630B-472A-9E9D-402DF383BE13Q26996818-1A2EDA16-6A0A-4410-85C9-C0D821FA6DAAQ26998811-75B8F8E8-21B7-41F2-B501-BB1880F9CD9DQ27612411-991DD56A-6519-4360-9E1B-2F5044DC5BBDQ27851436-839F6466-3E64-4541-94AA-7C710EF27D47Q27851460-330E073F-4BDB-4C9F-8141-D1A15AEBB844Q27851726-385C50D1-D99D-4046-97F7-2FFD4DD70157Q27851839-0EE3B56E-154F-4609-ADC7-B92BB8A0DCAAQ27853004-F11AA37C-9A81-4DDF-ACEC-16170E8591C0Q28077082-D998CAE4-1AF5-40FF-9EA3-221F44597280Q28301344-778813E5-6D50-4970-97BB-7E02A6C2E085Q31111079-4B8A6402-AC95-4730-A8E2-017CEC5BB58FQ33257982-382D91E0-381F-4C78-A5B6-37521B156DF0Q33573806-F1ADA39C-B077-4E97-A546-568B4B4F0246Q33897586-23D17277-AD2C-4000-9DC2-87799C2D6986Q33939071-221944D6-E458-4BEF-AC73-145A93FC032EQ34156717-28ED6B2D-F121-4A5A-8D43-A95DD58C5D0CQ34233639-6EAFEBD5-0F27-496C-81D1-951140E161A9Q34388725-F4BB8A68-B8EB-4B19-B53E-DB7E20A00A0FQ34502042-F3A6B6BA-3E3B-4394-812C-1BA2540267D9Q34502869-131F55C4-634D-41F7-9356-6994E424287CQ34522735-18595A7B-0224-4F9B-9881-C5B6B4DB9E00Q34541735-323D0843-4E50-4691-9F56-8184CC963703Q34541748-2F6EF202-492C-4ACE-8CD3-043B818B21EAQ34542996-642EA5A8-789A-4368-8771-FD5AF40413ABQ34612599-430D8447-4048-4221-839C-2BF097C10984Q34632079-9A3057EF-3A0B-41D0-A7FE-89A866B889FDQ34649120-B7751B27-A10B-410D-9A8E-BDB135185795Q34667807-DF2C2D75-972B-4468-80E5-77B809B73BD7Q34890418-27356CFF-6DF1-4FDC-9B71-C495FAF88ED0Q34924432-112AFB7E-C07B-4175-A2D7-5404F5D5E289Q34930673-DA766D3A-6DB9-4B02-8B8E-F1051B6380F6Q34995939-E9B11DC4-B077-4EB6-8DCC-1BA7BCDAD531Q35006113-AD57BE2B-6648-4C33-A2EA-D5EF05AAF9CAQ35007333-4068F2AB-3BB9-41DB-99B7-0313BBC4A4DFQ35043364-4DF08236-CB41-456A-809D-96402BABEE09Q35048217-1F60BBBB-A427-461E-9D97-D1CE92732041Q35083685-280D2293-1D44-4011-9486-C3FE842E2A35
P2860
CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations.
description
2004 nî lūn-bûn
@nan
2004 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
CEBPA mutations in younger adu ...... ysis of cooperating mutations.
@ast
CEBPA mutations in younger adu ...... ysis of cooperating mutations.
@en
CEBPA mutations in younger adu ...... ysis of cooperating mutations.
@nl
type
label
CEBPA mutations in younger adu ...... ysis of cooperating mutations.
@ast
CEBPA mutations in younger adu ...... ysis of cooperating mutations.
@en
CEBPA mutations in younger adu ...... ysis of cooperating mutations.
@nl
prefLabel
CEBPA mutations in younger adu ...... ysis of cooperating mutations.
@ast
CEBPA mutations in younger adu ...... ysis of cooperating mutations.
@en
CEBPA mutations in younger adu ...... ysis of cooperating mutations.
@nl
P2093
P3181
P356
P1476
CEBPA mutations in younger adu ...... ysis of cooperating mutations.
@en
P2093
Axel Benner
Ina Stolze
Jörg Bihlmayr
Karen Tobis
Richard F Schlenk
Stefan Fröhling
Sylvia Kreitmeier
P304
P3181
P356
10.1200/JCO.2004.06.060
P407
P577
2004-02-15T00:00:00Z